8-K

                    U. S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D. C. 20549

                                    FORM 8-K

                     Pursuant to Section 13 or 15 (d) of the
                         Securities Exchange Act of 1934


Date of Report:   February 12, 2001


Commission file number    0-19866
                          -------


                            CELOX LABORATORIES, INC.
                            ------------------------
                     (Exact name of small business issuer as
                            specified in its charter)


             MINNESOTA                                    36-3384240
             ---------                                    ----------
 (State or other jurisdiction                         (I.R.S. Employer
 of incorporation or organization)                    Identification Number)

 1311 HELMO AVENUE, ST. PAUL, MINNESOTA                      55128
 -----------------------------------------                   -----
 (Address of principal executive offices)                  (Zip code)


Issuers telephone number, including area code:   (651) 730-1500


Item 5. OTHER EVENTS MERGER OF CELOX LABORATORIES, INC WITH PROTIDE
        -----------------------------------------------------------
        PHARMACEUTICALS, INC.
        ---------------------

        On January 12, 2001. Celox Laboratories, Inc. announced a merger with
its wholly owned subsidiary, Protide Pharmaceuticals, Inc.

Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
        ----------------------------------

        (c.)  Exhibits.

        *Exhibit 17  Press Release dated January 12, 2001.

- -----------------------------------




                                    SIGNATURE
                                    ---------
        Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                                     Celox  Laboratories,  Inc.

January 29, 2001                                     By  /s/ Milo R. Polovina
                                                         Milo R. Polovina, CEO

EX-99

                                                                      EXHIBIT 17


FOR IMMEDIATE RELEASE

Contact:  Milo R. Polovina, Chairman and CEO
          David E. Tess, Vice President Finance and Administration
          (651) 730-1500

Date:     January 12, 2001

MERGER OF CELOX LABORATORIES, INC AND PROTIDE PHARMACEUTICALS, INC.

ST. PAUL, MINN, JANUARY 12, 2001 -- CELOX Laboratories, Inc., (OTCBB: CELX) and
its wholly owned subsidiary, Protide Pharmaceuticals, Inc.(Protide), announced
today the merger of the two companies with the surviving corporation to be named
Protide Pharmaceuticals, Inc. The ticker symbol for Protide on the OTCBB will be
"PPMD", effective January 12, 2001. Shareholders of Celox Laboratories, Inc.
will not be required to exchange their shares for new certificates. The
Company's corporate headquarters will remain at 1311 Helmo Ave. N., St. Paul, MN
55128.

"The merger reflects the combinatorial expertise of the two organizations,
strengthening our technology platform in Clinical Cell Therapy (CCT) and
transfusion medicine" stated Milo R. Polovina, Chairman, President and CEO.

The Company has several products at various stages of development including
ViaStem(TM) which was developed for the cryopreservation and transfusion of stem
cells from bone marrow, peripheral blood and umbilical cord blood. The Company
hopes to begin clinical trials for ViaStem in the near future.

The Company recently introduced Stemsol(TM) for the preservation of stem cells
and HemaPro(TM) an EX VIVO expansion solution.

Protide Pharmaceuticals, Inc. is a biotechnology company devoted to the
discovery, development and commercialization of technologies and processes in
clinical cell therapy and transfusion medicine, specifically in the areas of
cancer, genetic disorders, cell engineering and transplantation.

The statements made in this press release may contain certain forward-looking
statements that involve a number of risks and uncertainties. Under the safe
harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995,
Celox/Protide cautions investors and others that any forward-looking statements
or projections made by the companies, including those made in this press
release, are subject to risks and uncertainties that may cause actual results to
differ from those projected. In addition, the risk factors listed from time to
time in the company's SEC filings, including but not limited to its Annual
Report on Form 10-KSB for the year ended August 31, 2000, may affect the actual
results achieved by the company.

                                      ###